CorVel Corporation (CRVL)
NASDAQHealth CareInsurance - BrokersSnapshot 2026-09-09
$66.44-1.82%
Close 2026-09-09 · 1-day change
NASDAQHealth CareInsurance - BrokersSnapshot 2026-09-09
Intact: The reason to own it still holds.
CorVel grows revenue about 7% a year. Profit margins stay stable. The company expands its CERIS prepay solutions. Free cash flow yield is steady near 3%.
Revenue growth could slow below 7%. Profit margins might compress from rising costs. CEO transition could disrupt execution. Valuation is elevated with a PE over 30.
The price is about 1% above our fair value near $63. Analysts expect roughly 7% revenue growth. Our view aligns with these expectations.
Breaks if: CERIS solution expansion stalls or reverses
Breaks if: Free cash flow yield falls below 3%
Profit margins decline significantly below recent levels
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a stable growth opportunity with a focus on expanding services and leveraging technology. The current thesis is intact, supported by strong recent financial performance and management's commitment to key priorities.
The market appears to have a neutral valuation stance, with a slight premium compared to peers. There is a modest expectations gap, suggesting that investors are not overly optimistic but are aware of the company's potential.
Fundamentals are likely to remain strong, given the robust earnings quality and management's focus on growth areas. However, there is a near-term risk of missing earnings expectations, as the company has a history of recent misses.
The thesis hinges on management's ability to execute on their priorities, particularly in expanding CERIS prepay solutions and investing in AI. Additionally, broader sector performance and economic indicators, like the jobs report, will influence CRVL's trajectory.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: YoY revenue growth falls below 7% next year
Over the next 1 to 3 years, CRVL's performance will depend on execution and external economic factors. Not investment advice.